



ISSN NO. 2320-5407

Journal homepage: <http://www.journalijar.com>

INTERNATIONAL JOURNAL  
OF ADVANCED RESEARCH

## REVIEW ARTICLE

# MICROSPHERE AS DRUG CARRIER: A REVIEW

\* Hire N.N , Dr. Derle D.V

M.V.P.Samaj<sup>3</sup> College of Pharmacy, Department of Pharmaceutics Shivaji Nagar Gangapur Road Nashik, M.S. India.

### Manuscript Info

#### Manuscript History:

Received: 15 January 2014  
Final Accepted: 23 February 2014  
Published Online: March 2014

#### Key words:

microspheres, characterisation of  
microspheres, drug delivery

#### \*Corresponding Author

Hire N.N

### Abstract

Development of microspheres is a promising technology for controlled release and drug targeting. Various types of microspheres such as bio-adhesive, magnetic, floating, radioactive and polymeric microspheres are developed for various purposes. Microspheres occupied a central place in novel drug delivery. There are various departments of medicine like cancer, pulmonary, cardiology, radiology, gynaecology, and oncology etc, numerous drugs are used and they are delivered by various types of drug delivery system. Among them microspheric drug delivery system has gained enormous attention due to its wide range of application as it covers targeting the drug to particular site to imaging and helping the diagnostic features. It also has advantage over various other dosage forms like we know for lung disease now a days aerosolised drugs are used for local delivery of drugs but it has disadvantage of shorter duration of action so for sustained release and reducing side effects and hence to achieve better patient compliance microspheres can be used. It also has advantage over liposomes as it is physicochemically more stable. Moreover the microspheres are of micron size so they can easily fit into various capillary beds which are also having micron size. The purpose of the review is to compile various types of microspheres, different methods to preparation, its applications and also various parameters to evaluate their efficiency.

Copy Right, IJAR, 2014,. All rights reserved.

### Introduction

The drug has to be delivered for a prolonged period of time and many medicines have to be taken simultaneously in case of chronic patients. Frequent administration of drug is necessary when those have shorter half life and all these leads to decrease in patient's compliance<sup>1</sup>. In order to overcome the above problems, various types of controlled release dosage forms are formulated and altered, so that patient compliance increase through prolonged effect, adverse effect decreases by lowering peak plasma concentration.<sup>2</sup> The controlled release dosage form maintaining relatively constant drug level in the plasma by releasing the drug at a predetermined rate for an extended period of time. One such in Microspheres as carriers of drug become an approach of controlled release dosage form in novel drug delivery system.<sup>2</sup> Microspheres are defined as "Monolithic sphere or therapeutic agent distributed more miscible polymers in which drug particles are dispersed at the molecular or macroscopic level."<sup>4</sup> It has a particle size of (1-1000nm).<sup>3</sup> Further, currently available slow release oral dosage forms, such as enteric coated/ double-layer tablets which release the drug for 12-24 hours still result in inefficient systemic delivery of the drug and potential gastrointestinal irritation. Microencapsulation for oral use has been employed to sustain the drug release, and to reduce or eliminate gastrointestinal tract irritation. In

addition, multiparticulate delivery systems spread out more uniformly in the gastrointestinal tract. This results in more reproducible drug absorption and reduces local irritation when compared to single-unit dosage forms such as non-disintegrating, polymeric matrix tablets. Unwanted intestinal retention of the polymeric material, which may occur with matrix tablets on chronic dosing, can also be avoided.<sup>4</sup> Microencapsulation is used to modify and retard drug release. Due to its small particle size, are widely distributed throughout the gastrointestinal tract which improves drug absorption and reduces side effects due to localized build-up of irritating drugs against the gastrointestinal mucosa.

#### **Advantages of Microspheres<sup>10</sup>:**

1. They facilitate accurate delivery of small quantities of potent drug and reduce concentration of drug at site other than the target organ or tissue.
2. They provide protection for unstable drug before and after administration, prior to their availability at the site of action.
3. They provide the ability to manipulate the *in vivo* action of the drug, pharmacokinetic profile, tissue distribution and cellular interaction of the drug.
4. They enable controlled release of drug. Examples: Narcotic, Antagonist, Steroid Hormones

## **TYPES OF MICROSPHERES**

### **Bioadhesive microspheres**

Adhesion can be defined as sticking of drug to the membrane by using the sticking property of the water soluble polymers. Adhesion of drug delivery device to the mucosal membrane such as buccal, ocular, rectal, nasal etc can be termed as bioadhesion. These kinds of microspheres exhibit a prolonged residence time at the site of application and causes intimate contact with the absorption site and produces better therapeutic action.<sup>6</sup> The effect of different polymers on bio adhesive microspheres are given in table I.

### **Magnetic microspheres**

This kind of delivery system is very much important which localises the drug to the disease site. In this larger amount of freely circulating drug can be replaced by smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic responses to a magnetic field from incorporated materials that are used for magnetic microspheres are chitosan, dextran etc.<sup>5</sup> The different types are Therapeutic magnetic microspheres: Are used to deliver chemotherapeutic agent to liver tumour. Drugs like proteins and peptides can also be targeted through this system.<sup>6</sup>

Diagnostic microspheres: Can be used for imaging liver metastases and also can be used to distinguish bowel loops from other abdominal structures by forming nano size particles superparamagnetic iron oxides.<sup>7</sup>

### **Floating microspheres**

In floating types the bulk density is less than the gastric fluid and so remains buoyant in stomach without affecting gastric emptying rate. The drug is released slowly at the desired rate, if the system is floating on gastric content and increases gastric residence and increases fluctuation in plasma concentration. Moreover it also reduces chances of striking and dose dumping. One another way it produces prolonged therapeutic effect and therefore reduces dosing frequencies. Drug (ketoprofen) given through this form<sup>8</sup>

### **Radioactive microspheres**

Radio embolisation therapy microspheres sized 10-30 nm are of larger than capillaries and gets trapped in first capillary bed when they come across. They are injected to the arteries that lead to tumour of interest. So all these conditions radio active microspheres deliver high radiation dose to the targeted areas without damaging the normal surrounding tissues.<sup>9</sup> It differs from drug delivery system, as radio activity is not released from microspheres but acts from within a radioisotope typical distance and the different kinds of radioactive microspheres are  $\alpha$  emitters,  $\beta$  emitters,  $\gamma$  emitters.<sup>10</sup>

### **Polymeric microspheres**

The different types of polymeric microspheres can be classified as follows and they are biodegradable polymeric microspheres and Synthetic polymeric microspheres.

#### **Biodegradable polymeric microspheres**

Natural polymers such as starch are used with the concept that they are biodegradable, biocompatible, and also bio adhesive in nature Biodegradable polymers prolongs the residence

time when contact with mucous membrane due to its high degree of swelling property with aqueous medium, results gel formation. The rate and extent of drug release is controlled by concentration of polymer and the release pattern in a sustained manner. The main drawback is, in clinical use drug loading efficiency of biodegradable microspheres is complex and is difficult to control the drug release. However they provide wide range of application in microsphere based treatment<sup>11</sup>

### **Synthetic polymeric microspheres**

The interest of synthetic polymeric microspheres are widely used in clinical application, moreover that also used as bulking agent, fillers, embolic particles, drug delivery vehicles etc and proved to be safe and biocompatible.<sup>11</sup> But the main disadvantage of these kind of microspheres, are tend to migrate away from injection site and lead to potential risk, embolism and further organ damage.<sup>12</sup>

## **METHOD OF PREPERATION**

Incorporation of solid, liquid or gases into one or more polymeric coatings can be done by micro encapsulation technique.<sup>1</sup> The different methods used for various microspheres preparation depends on particle size, route of administration, duration of drug release and these above characters related to rpm, method of cross linking, drug of cross linking, evaporation time, co-precipitation etc.<sup>5</sup> The various methods of preparations are

### **Emulsion solvent evaporation technique**

In this technique the drug is dissolved in polymer which was previously dissolved in chloroform and the resulting solution is added to aqueous phase containing 0.2% sodium of pvp as emulsifying agent. The above mixture was agitated at 500 rpm then the drug and polymer (eudragit) was transformed into fine droplet which solidified into rigid microspheres by solvent evaporation and then collected by filtration and washed with demineralised water and desiccated at room temperature for 24 hrs.<sup>12</sup> Aceclofenac microspheres were prepared by this technique.

### **Emulsion cross linking method**

In this method drug was dissolved in aqueous gelatine solution which was previously heated for 1 hr at 40 °C. The solution was added drop wise to liquid paraffin while stirring the mixture at 1500 rpm for 10 min at 35 °C, results in w/o emulsion then further stirring is done for 10 min at 15 °C. Thus the produced microspheres were respectively three times with acetone and isopropyl alcohol which then air dried and dispersed in 5 mL of aqueous glutaraldehyde saturated toluene solution at room temperature for 3 hrs for crosslinking and then was treated with 100 mL of 10% glycine solution containing 0.1% w/v of tween 80 at 37 °C for 10 min to block unreacted glutaraldehyde.<sup>18</sup> Examples for this technique is Gelatin A microspheres.

### **Co-acervation method**

Co-acervation thermal change: Performed by weighed amount of ethyl cellulose was dissolved in cyclohexane with vigorous stirring at 80 °C by heating. Then the drug was finely pulverised and added with vigorous stirring on the above solution and phase separation was done by reducing temperature and using ice bath. Then above product was washed twice with cyclohexane and air dried then passed through sieve (sieve no. 40) to obtain individual microcapsule.<sup>1</sup>

Co-acervation non solvent addition: Developed by weighed amount of ethyl cellulose was dissolved in toluene containing propylisobutylene in closed beaker with magnetic stirring for 6 hr at 500 rpm and the drug is dispersed in it and stirring is continued for 15 mins. Then phase separation is done by petroleum benzoin 5 times with continuous stirring.<sup>1</sup> After that the microcapsules were washed with n-hexane and air dried for 2 hr and then in oven at 50 °C for 4 hr.<sup>1</sup>

### **Spray drying technique**

This was used to prepare polymeric blended microsphere loaded with ketoprofen drug. It involves dispersing the core material into liquefied coating material and then spraying the mixture in the environment for solidification of coating followed by rapid evaporation of solvent.<sup>4</sup> Organic solution of poly (epsilon-caprolactone) (PCL) and cellulose acetate butyrate (CAB), in different weight ratios and ketoprofen were prepared and sprayed in different experimental condition achieving drug loaded microspheres. This is rapid but may lose crystallinity due to fast drying process.<sup>4</sup>

### **Emulsion-solvent diffusion technique**

In order to improve the residence time in colon floating microparticles of ketoprofen were prepared using emulsion solvent diffusion technique. The drug polymer mixture was dissolved in a mixture of ethanol and dichloromethane (1:1) and then the mixture was added drop wise to sodium lauryl

sulphate (SLS) solution. The solution was stirred with propeller type agitator at room temperature at 150 rpm for 1 hr. Thus the formed floating microspheres were washed and dried in a desiccator at room temperature. The following microparticles were sieved and collected.<sup>4</sup>

#### **Multiple emulsion method**

Oral controlled release drug delivery of indomethacin was prepared by this technique. In the beginning powder drug was dispersed in solution (methyl cellulose) followed by emulsification in ethyl cellulose solution in ethylacetate. The primary emulsion was then re-emulsified in aqueous medium. Under optimized condition discrete microspheres were formed during this phase.<sup>4</sup>

#### **Ionic gelation**

Alginate/chitosan particulate system for diclofenac sodium release was prepared using this technique. 25 % (w/v) of diclofenac sodium was added to 1.2 % (w/v) aqueous solution of sodium alginate. In order to get the complete solution stirring is continued and after that it was added dropwise to a solution containing  $Ca^{2+}$  /  $Al^{3+}$  and chitosan solution in acetic acid. Microspheres which were formed were kept in original solution for 24 hr for internal gelification followed by filtration for separation. The complete release was obtained at pH 6.4-7.2 but the drug did not release in acidic pH.<sup>4</sup>

#### **Hydroxyl apatite (HAP) microspheres in sphere morphology**

phase (Diclofenac sodium containing 5% w/w of EVA and appropriate amount of HAP) in aqueous phase of surfactant. The organic phase was dispersed in the form of tiny droplets which were surrounded by surfactant molecules this prevented the droplets from co-solvening and helped them to stay individual droplets. While stirring the DCM was slowly evaporated and the droplets solidify individual to become microspheres.<sup>19</sup>

## **CHARACTERIZATION/ EVALUATION OF MICROSPHERES**

#### **Particle size analyser**

Microsphere (50 mg) was suspended in distilled water (5mL) containing 2% w/v of tween 80, To prevent microsphere aggregation, the above suspension is sonicated in water bath and the particle size was expressed as volume mean diameter in micrometer.<sup>20</sup>

#### **Optical microscopy**

This method was used to determine particle size by using optical microscope (Meizer OPTIK) The measurement was done under 450x (10x eye piece and 45x objective) and 100 particles were calculated.<sup>21</sup>

#### **Scanning electron microscopy (SEM)**

Surface morphology was determined by the method SEM. In this microcapsule were mounted directly on the SEM sample stub with the help of double sided sticking tape and coated with gold film under reduced pressure.<sup>22</sup>

#### **Swelling index**

This technique was used for characterization of sodium alginate microspheres were performed with swelling index technique. Different solutions (100mL) were taken such as (distilled water, buffer solution of pH (1.2, 4.5, 7.4) were taken and alginate microspheres (100mg) were placed in a wire basket and kept on the above solution and swelling was allowed at 37 °C and changes in weight variation between initial weight of microspheres and weight due to swelling was measured by taking weight periodically and soaking with filter paper.<sup>23</sup>

#### **Entrapment efficiency**

Microspheres containing drug (5mg) were crushed and then dissolved in distilled water with the help of ultrasonic stirrer for 3 hr, and was filtered then assayed by uv-vis spectroscopy. Entrapment efficiency is equal to ratio of actual drug content to theoretical drug content.<sup>23</sup>

#### **X-ray diffraction**

Change in crystallinity of drug can be determined by this technique. Microparticles and its individual components were analysed by the help of D & Discover (Bruker, Germany). Scanning range angle between 8 °C - 70 °C. Scan speed - 4°/min Scintillation detector Primary slit = 1mm Secondary slit = 0.6 mm.<sup>1</sup>

#### **Thermal analysis**

Thermal analysis of microcapsule and its component can be done by using-Differential scanning calorimetry (DSC)Thermo gravimetric analysis (TGA)Differential thermometric analysis (DTA)Accurately the sample was weighed and heated on alumina pan at constant rate of 10oc/min under nitrogen flow of 40 ml/min.1

#### **UV-FTTR (Fourier transform infra red)**

The drug polymer interaction and also degradation of drug while processing for microencapsulation can be determined by FTIR.

#### **Stability studies**

By placing the microspheres in screw capped glass container and stored them at following conditions:

1. Ambient humid condition
2. Room temperature ( $27\pm 2^{\circ}\text{C}$ )
3. Oven temperature ( $40\pm 2^{\circ}\text{C}$ )
4. Refrigerator ( $5^{\circ}\text{C} - 8^{\circ}\text{C}$ ).

It was carried out of a 60 days and the drug content of the microsphere was analyzed.

#### **Zeta potential**

The polyelectrolyte shell was prepared by incorporating chitosan of different molecular weight into the W2 phase and the resulting particles were determined by zeta potential measurement.

#### **Invitromethods<sup>39,40,41</sup>**

There is a need for experimental methods which allow the release characteristics and permeability of a drug through membrane to be determined. For this purpose, a number of in vitro and in vivo techniques have been reported. In vitro drug release studies have been employed as a quality control procedure in pharmaceutical production, in product development etc. Sensitive and reproducible release data derived from physicochemically and hydro dynamically defined conditions are necessary. The influence of technologically defined conditions and difficulty in simulating in vivo conditions has led to development of a number of in vitro release methods for buccal formulations; however no standard in vitro method has yet been developed. Different workers have used apparatus of varying designs and under varying conditions, depending on the shape and application of the dosage form developed.

#### **Interface diffusion system**

This method is developed by Dearden & Tomlinson. It consists of four compartments. The compartment A represents the oral cavity, and initially contained an appropriate concentration of drug in a buffer. The compartment B representing the buccal membrane, contained 1-octanol, and compartment C representing body fluids, contained 0.2 M HCl. The compartment D representing protein binding also contained 1-octanol. Before use, the aqueous phase and 1-octanol were saturated with each other. Samples were withdrawn and returned to compartment A with a syringe.

#### **Dissolution apparatus**

Standard USP or BP dissolution apparatus have been used to study in vitro release profiles using rotating elements, paddle and basket. Dissolution medium used for the study varied from 100-500 ml and speed of rotation from 50-100 rpm.

#### **Invivomethods<sup>41</sup>**

Methods for studying the permeability of intact mucosa comprise of techniques that exploit the biological response of the organism locally or systemically and those that involve direct local measurement of uptake or accumulation of penetrate at the surface. Some of the earliest and simple studies of mucosal permeability utilized the systemic pharmacological effects produced by drugs after application to the oral mucosa. However the most widely used methods include invivostudies using animal models, buccal absorption tests, and perfusion chambers for studying

drug permeability.

### **Animal models**

Animal models are used mainly for the screening of the series of compounds, investigating the mechanisms and usefulness of permeation enhancers or evaluating a set of formulations. A number of animal models have been reported in the literature, however, very few *in vivo* (animal). Animal models such as the dog, rats, rabbits, cat, hamster, pigs, and sheep have been reported. In general, the procedure involves anesthetizing the animal followed by administration of the dosage form. In case of rats, the oesophagus is ligated to prevent absorption pathways other than oral mucosa. At different time intervals, the blood is withdrawn and analyzed.

### **Buccal absorption test**

The buccal absorption test was developed by Beckett & Triggs in 1967. It is a simple and reliable method for measuring the extent of drug loss of the human oral cavity for single and multicomponent mixtures of drugs. The test has been successfully used to investigate the relative importance of drug structure, contact time, initial drug concentration and pH of the solution while the drug is held in the oral cavity.

### **Invitro-Invivocorrelations**

Correlations between *in vitro* dissolution rates and the rate and extent of availability as determined by blood concentration and or urinary excretion of drug or metabolites are referred to as “*in vitro-in vivo* correlations”. Such correlations allow one to develop product specifications with bioavailability.

## **APPLICATION**

### 1. Microspheres in vaccine delivery<sup>42,43</sup>

The prerequisite of a vaccine is protection against the micro organism or its toxic product. An ideal vaccine must fulfill the requirement of efficacy, safety, convenience in application and cost. The aspect of safety and minimization of adverse reaction is a complex issue. The aspect of safety and the degree of the production of antibody responses are closely related to mode of application. Biodegradable delivery systems for vaccines that are given by parenteral route may overcome the shortcoming of the conventional vaccines<sup>49</sup>. The interest in parenteral (subcutaneous, intramuscular, intradermal) carrier lies since they offer specific advantages including:

- Improved antigenicity by adjuvant action
- Modulation of antigen release
- Stabilization of antigen.

### 2. Targeting using microparticulate carriers<sup>44,45</sup>

The concept of targeting, i.e. site specific drug delivery is a well established dogma, which is gaining full attention. The therapeutic efficacy of the drug relies on its access and specific interaction with its candidate receptors. The ability to leave the pool in reproducible, efficient and specific manner is center to drug action mediated by use of a carrier system. Placement of the particles indiscrete anatomical compartment leads to their retention either because of the physical properties of the environment or biophysical interaction of the particles with the cellular content of the target tissue.

### 3. Monoclonal antibodies mediated microspheres targeting<sup>46</sup>

Monoclonal antibodies targeting microspheres are immune microspheres. This targeting is a method used to achieve selective targeting to the specific sites. Monoclonal antibodies are extremely specific molecules. This extreme specificity of monoclonal antibodies (Mabs) can be utilized to target microspheres loaded bioactive molecules to selected sites. Mabs can be directly attached to the microspheres by means of covalent coupling. The free aldehyde groups, amino groups or hydroxyl groups on the surface of the microspheres can be linked to the antibodies. The

Mabs can be attached to microspheres by any of the following methods

1. Non specific adsorption
2. Specific adsorption
3. Direct coupling
4. Coupling via reagents

#### 4. Imaging

The microspheres have been extensively studied and used for the targeting purposes. Various cells, cell lines, tissues and organs can be imaged using radio labelled microspheres. The particle size range of microspheres is an important factor in determining the imaging of particular sites. The particles injected intravenously apart from the portal vein will become entrapped in the capillary bed of the lungs. This phenomenon is exploited for the scintigraphic imaging of the tumour masses in lungs using labeled human serum albumin microspheres.

#### 5. Topical porous microspheres<sup>48,59</sup>

Microsponges are porous microspheres having myriad of interconnected voids of particle size range 5-300  $\mu\text{m}$ . These microsponges having capacity to entrap wide range of active ingredients such as emollients, fragrances, essential oils etc., are used as the topical carriers system further, these porous microspheres with active ingredients can be incorporated into formulations such as creams, lotions and powders. Microsponges consist of non collapsible structures with porous surface through which active ingredients are released in a controlled manner.

#### 6. Surface modified microspheres<sup>50</sup>

Different approaches have been utilized to change the surface properties of carriers to protect them against phagocytic clearance and to alter their body distribution patterns. The adsorption of the poloxamer on the surface of the polystyrene, polyester or poly methyl methacrylate microspheres renders them more hydrophilic and hence decrease their MPS uptake. Protein microspheres covalently modified by PEG derivatives show decreased immunogenicity and clearance. The most studied surface modifiers are:

1. Antibodies and their fragments
2. Proteins
3. Mono- oligo- and polysaccharides
4. Chelating compounds (EDTA, DTPA or Desferroxamine)
5. Synthetic soluble polymers such modifications are provided surface of microspheres in order to achieve the targeting to the discrete organs and to avoid rapid clearance from the body.

#### 6. Microspheres for DNA Delivery<sup>51,52</sup>

Microspheres have been recently used as a delivery vehicle for the transfer of plasmid DNA which leads to improve the transfer of plasmid DNA and their stability in the bio- environment. Truong-Le & Co workers (1998) developed a novel system for gene delivery based on the use of DNA-gelatin microspheres/ nanoparticles formed by salt induced complex coacervation of gelatin & plasmid DNA as shown in table

#### 7. Microspheres for Lymph targeting<sup>53</sup>

The major purpose of lymph targeting is to provide an effective anticancer chemotherapy to prevent the metastasis of tumor cells by accumulating the drug in the regional lymph node. Example:  
Poly alkyl cyanoacrylate microspheres bearing anticancer drugs for tumor of peritoneal cavity.  
Poly (lactide-co-glycolide) microspheres for the lymphatic of diagnostic agents.

## Pharmaceutical Applications In Drug Delivery System

### 1. Ophthalmic Drug Delivery<sup>54</sup>

Polymer exhibits favorable biological behavior such as bioadhesion, permeability-enhancing properties, and interesting physico-chemical characteristics, which make it a unique material for the design of ocular drug delivery vehicles. Due to their elastic properties, polymer hydro gels offer better acceptability, with respect to solid or semisolid formulation, for ophthalmic delivery, such as suspensions or ointments, ophthalmic chitosan gels improve adhesion to the mucin, which coats the conjunctiva and the corneal surface of the eye, and increase precorneal drug residence times, showing down drug elimination by the lachrymal flow.

### 2. Gene delivery<sup>55</sup>

Gene delivery systems include viral vectors, cationic liposomes, polycation complexes, and microencapsulated systems. Viral vectors are advantageous for gene delivery because they are highly efficient and have a wide range of cell targets. However, when used in vivo they cause immune responses and oncogenic effects. To overcome the limitations of viral vectors, non-viral delivery systems are considered for gene therapy. Non-viral delivery system has advantages such as ease of preparation, cell/tissue targeting, low immune response, unrestricted plasmid size, and large-scale reproducible production. Polymer has been used as a carrier of DNA for gene delivery applications.

### 3. Oral drug delivery<sup>56</sup>

The potential of polymer films containing diazepam as an oral drug delivery was investigated in rabbits. The results indicated that a film composed of a 1:0.5 drug-polymer mixture might be an effective dosage form that is equivalent to the commercial tablet dosage forms. The ability of polymer to form films may permit its use in the formulation of film dosage forms, as an alternative to pharmaceutical tablets. The pH sensitivity, coupled with the reactivity of the primary amine groups, make polymer a unique polymer for oral drug delivery applications.

### 4. Nasal drug delivery<sup>57</sup>

The nasal mucosa presents an ideal site for bioadhesive drug delivery systems. Polymer based drug delivery systems, such as micro spheres, liposomes and gels have been demonstrated to have good bioadhesive characteristics and swell easily when in contact with the nasal mucosa increasing the bioavailability and residence time of the drugs to the nasal route. Various polymer salts such as chitosan lactate, chitosan aspartate, chitosan glutamate and chitosan hydrochloride are good candidates for nasal sustained release of vancomycin hydrochloride.

## CONCLUSION

Microspheres form an important drugdelivery strategy for controlled release and targeting. Microspheres containing anti neoplasticdrugs, steroid hormones, vaccines, proteins and peptides, antiviral, antifungal andantibiotic drugs, anti-diabetic drugs and anti inflammatory drugs are investigatedextensively for controlled release by various routes and for targeting. In recent years studieson microspheres have been increased as it has become a promising technology in the areas ofdrug delivery, proteomics and genomics and also for studying bio molecular interactions.

**Table 1:** Summary of Recent Research on Microspheres

| Sr. No | Drug/Category Polymers Used                    | Polymers Used            | Method of Preparation  | Purpose / Result   | Refer ence |
|--------|--|--------------------------|------------------------|--|------------|
| 1      | Cephalexin (Antibiotic)                        | Sodium alginate, Guargum | Ion gelation technique | Mucoadhesive polymers Guar gum in combination with sodiualginate provides extended gastric retention and has ability to coat gastric mucosa Uniformly. | 11         |
| 2      | Propanolol Hydro chloride (Anti Hypertensive ) | Sodium carboxy methyl    | cellulose, carbopol    | 934p, HPMCK4M  | 12         |



|    |   |  |   |   |    |
|----|---|--|---|---|----|
| 3  | Sitagliptin phosphate (Anti Diabetic)                               | Eudragit RS100,HPMC  | Non aqueous solventevaporation technique                      | Prolonging gastric retention of the dosage form   | 13 |
| 4  | Aceclofenac (NSAID)   | EUDRAGIT S 100, EUDRAGIT L 100                                 | Response surface methodology                                  | Increase gastric residence of the drug  | 14 |
| 5  | Cephalexin (Antibiotic)   | Ethyl cellulose  | Emulsion solvent evaporation                                  | Prolonged drug release in the stomach at least 12 hrs   | 15 |
| 6  | Salbutamol sulphate (Anti Asthmatic), theophylline (Anti Asthmatic) | Ethyl cellulose  | Emulsion solvent evaporation                                  | Matrix microspheres have a potential for the prolongation and simultaneous delivery of drugs  | 16 |
| 7  | Mefenamic acid (NSAID)  | Chitosan   | Thermal andGlutaraldehyde cross linking                       | Use of chitosan to control the release of poorly water soluble drugs  | 17 |
| 8  | Salbutamol sulphate (Broncho Dilator)                               | Chitosan   | Spray drying method   | Spray drying is useful for preparation of salbutamol sulphate loaded chitosan microspheres in presence of and absence of crosslinking agent | 18 |
| 9  | Aceclofenac (NSAID)   | Sodium alginate  | Ionic gelation Method   | Decrease the dosing frequency and also prevent gastric hemarrahage  | 19 |
| 10 | Perindopril erbumine (Anti Hypertensive)                            | Ethyl cellulose, HPMC, PVP K30, EUDRAGIT S 100, PVPK90         | Double emulsion solvent diffusion method                      | Prolong the drug release in a stomach for up to 12 hrs  | 20 |
| 11 | Losartan (Anti Hypertensive)  | Ethyl cellulose, Sodium alginate, Acycoat L30D, Acycoat E 30 D | Solvent evaporation, w/o emulsion, solvent evaporation method | Solvent evaporation method gives Maximum yield.   | 21 |
| 12 | Losartan potassium (Anti Hypertensive)                              | Chitosan, Sodium alginate                                      | Emulsification solvent evaporation method                     | Smoothness of the losartan potassium microspheres was increased by increasing polymer concentration   | 22 |
| 13 | Glipizide (Anti Diabetic)   | Acrycoat S100 USP, Eudragit RS100                              | Emulsion solvent diffusion technique                          | Maintain a constant drug concentration in the serum for a longer period of time   | 23 |
| 14 | Diltiazem hydrochloride (Anti Hypertensive)                         | Ethyl cellulose  | Emulsion solvent evaporation method                           | Enhance the uptake of hydrophilic substance across epithelial layer   | 24 |
| 15 | Metformin (Anti Diabetic)   | Ethylcellulose, HPMC, Carbopol 934 P, Chitosan                 | Non aqueous solvent evaporation method                        | Chitosan as a polymer exhibited maximum prolonged drug release  | 25 |

|    |   |   |   |  |    |
|----|---|---|---|--|----|
|    |   |   |   | at GIT PH or at least 15hrs  |    |
| 16 | Glimepiride<br>(Anti Diabetic)                | Ethyl Cellulose,<br>Eudragit RS 100,<br>Eudragit RL100                | Emulsification<br>solvent evaporation<br>method | Size of the microspheres was<br>increased with increasing<br>concentration of polymer  | 26 |
| 17 | Carvedilol<br>(Anti Hypertensive)             | Ethyl cellulose,<br>PEG 6000  | Spray drying                                    | The characterization of<br>microspheres revealed the<br>poor<br>flow ability of the spray dried  | 27 |
| 18 | Nifedipine<br>(Anti Hypertensive)             | Eudragit RL 100   | Solvent evaporation                             | Enhancing bioavailability  | 28 |
| 19 | Nifedipine<br>(Anti Hypertensive)             | Sodium<br>Alginate,<br>HPMC,<br>Carbopol                              | Ionic gelation<br>method                        | Drug release from<br>microspheres<br>was found slow followed by<br>first<br>order kinetics with non<br>Fickian<br>release mechanism  | 29 |
| 20 | Amoxicillin<br>trihydrate                     | Eudragit RS 100   | Solvent evaporation                             | Delivery of protein and<br>peptide<br>drugs  | 30 |
| 21 | (Anti Ritonovir<br>(Anti Viral)ibiotic)       | Mixture of<br>sodium<br>alginate and<br>HPMC                          | Ionic gelation<br>method                        | Increase the gastric retention<br>time<br>of drug  | 31 |
| 22 | Indomethacin<br>(NSAID)                       | Ethyl cellulose N<br>10,<br>Ethyl cellulose N<br>100                  | Emulsion solvent<br>evaporation                 | Ethylcellulose N10 and N100<br>membrane materials indicated<br>differences in release patterns<br>of<br>microspheres. Microspheres<br>exhibited lower burst effect<br>with<br>ethyl cellulose N100 | 32 |
| 23 | Metformin<br>hydrochloride<br>(Anti Diabetic) | Sodium Carboxy<br>Methyl<br>Cellulose,<br>Carbopol 934P,<br>HPMC K 4M | Emulsion solvent<br>evaporation                 | Reduce the dosing frequency<br>and<br>improving patient compliance<br>by<br>designing sustained release<br>Mucoadhesive microspheres   | 33 |
| 24 | Ascorbic acid                                 | (Anti Oxidant)  | Ethyl cellulose<br>coacervation<br>technique    | Derived properties of ascorbic<br>acid loaded microspheres, the<br>prepared product has uniform<br>size<br>and shape, spherical in particle<br>size and passable flow<br>property                  | 34 |
| 25 | Metformin Hcl<br>(Anti Diabetic)              | Eudragit RL 100,<br>cellulose acetate<br>butyrate                     | w/o emulsion solvent<br>evaporation method      | Drug loaded floating<br>microspheres will overcome<br>the<br>drawbacks associated with<br>drug in<br>conventional tablet form<br>reducing<br>plasma drug conc. fluctuations                        | 35 |

|    |                                  |   |  |  |    |
|----|----------------------------------|---|--|--|----|
| 26 | Lamivudine<br>(Anti Viral)       | Acryl coat L<br>30D and S<br>100                    | Solvent evaporation<br>method          | Plasma concentration was<br>maintained above the<br>minimum<br>effective concentration for<br>longer<br>time after administration of<br>microspheres                             | 36 |
| 27 | Meloxicam<br>(Anti Inflammatory) | Polyvinyl<br>Alcohol,<br>PEG 6000,<br>Gelatin       | Emulsion solvent<br>evaporation method | Emulsion solvent evaporation<br>method is suitable for<br>encapsulating lipophilic drugs.  | 37 |
| 28 | Glipizide<br>(Anti Diabetic)     | Ethyl Cellulose,<br>HPMC,<br>Methocel K 100<br>M CR | Solvent evaporation<br>method          | Use of this approach has the<br>potential not only to improve<br>the<br>Therapeutic effectiveness of<br>the<br>drug but also to allow a<br>reduction<br>in the total drug needed | 38 |

## REFERENCES

1. Ghulam M., Mahmood A., Naveed A., Fatima R.A., Comparative study of various microencapsulation techniques. Effect of polymer viscosity on microcapsule characteristics, Pak.J.Sci.2009; 22 (3):291-300.
2. Mathew Sam T., Devi Gayathri S., Prasanth V.V., Vinod B., Suitability of factorial design in determining the processing factors affecting entrapment efficiency of albumin microspheres, Journal of Pharmacy Research.2010; 3(5):1172-1177.
3. Karmakar U., Faysal M.M., Diclofenac as microspheres, The Internet Journal of Third World Medicine. 2009; 8(1)
4. Mathew Sam T., Devi Gayathri S., Prasanth V.V., Vinod B; NSAIDs as microspheres, The Internet Journal of Pharmacology .2008;6(1).
5. Li, S.P., Kowalski C.R., Feld K.M., Grim W.M., Recent Advances in Microencapsulation Technology and Equipment, Drug Dev Ind Pharm.1988; 14: 353-376.
6. www.pharmainfo.net/reviews/bioadhesivemicrospheres-review, 24th Nov 2010 Patel JK, Patel RP, Amin AF, Patel MM, 4(6), 12/16/2006.
7. Shanthi N.C., Dr. Gupta R., Mahato K.A., Traditional and Emerging Applications of Microspheres: A Review, International Journal of Pharm Tech Research. 2010; 2(1):675-681.
8. Najmuddin M., Ahmed A., Shelar S., Patel V., Khan T., Floating Microspheres Of Ketoprofen: Formulation and Evaluation, International Journal Of Pharmacy and Pharmaceutical sciences. 2010; 2(Suppl2):83-87.
9. <http://www.springerlink.com/content/r883r91q17576vx6/>, 25th Nov 2010, DOI: 10.1007/0-306-46891-3\_9, Hafeli U, 2002, Physics and Chemistry Basic of Biotechnology. Focus on biotechnology. Review. Radioactive Microspheres for Medical Application, 7:213-248.
10. T. Omkar, M. Alagusundaram, S.C. Madhu, Microspheres as a novel drug delivery system, Int J of Chem Tech and Res, 3(1), 2009, 526-534.
11. Shivhare D., Tijare P.M. Formulation and characterization of microspheres of selected anti-infective agent for urinary tract infection. Journal of drug delivery research, 2013; 2(1):16-26
12. Akashyadav, Formulation and evaluation of mucoadhesive microspheres of propranolol hydrochloride for sustained drug delivery. Asian journal of pharmacy and medical science, 2011; 1 (1):1-8
13. Vadaliyask, Vadaliyacr, Formulation and in-vitro evaluation of floating microspheres of anti-diabetic drug prepared by solvent evaporation method. International journal of pharmaceutical and chemical sciences, 2013; 2 (1):397-403
14. Shaji Jessy and Shinde A. Formulation and optimization of floating pulsatile aceclofenac microspheres using response surface methodology. International research journal of pharmacy 2012;

3(1):166-169

15. Kaminivasava, Rajesh KS, Lalitlatajha; Formulation and evaluation of floating microspheres of cephalexin. *International journal of pharmaceutical sciences review and research*, November – December 2011; 11(2):69-75
16. Pachuau, S Sarkar and B Mazumder. Formulation and evaluation of matrix microspheres for simultaneous delivery of salbutamol sulphate and theophylline. *Tropical journal of pharmaceutical research*, June 2008; 7 (2): 995-1002
17. Roy S Panpalia, S G, Nandyb.C, Raivk.Tyagi , K. Dey S , Meena K. Effect of method of preparation on chitosan microspheres of Mefenamic acid. *International journal of pharmaceutical sciences and drug research*, 2009; 1(1):36-42
18. Kamblemeghana S, Mane Omkar R, Mane Surajs, Borwandkarvarsha G, Chaudharipravin D. Formulation & characterization of chitosan based microspheres of salbutamol sulphate dry powder inhaler formulation. *Journal of drug delivery and therapeutics*, 2012; 2(5), 37-41
19. Madhu smruti khandai, Santanuchakraborty, Anuradha sharma, Satyanarayan patnaik, Ch. Niranjana. Preparation and evaluation of alginate-chitosan mucoadhesive microspheres as an approach for sustained drug. *Journal of advanced pharmaceutical research*, 2010; 1: 48-60
20. Aabdulhasan sathali. A. and Kathiravan.S; Formulation and characterization of floating microspheres of perindopril erbumine. *Journal of pharmacy research*, 2012; 5(4):
21. Ghoshprasanta K. Effect of method of preparation on physical properties and in vitro drug release profile of losartan microspheres – a comparative study. *International journal of pharmacy and pharmaceutical sciences*, 2009 1(1), 627-638
22. K. Kavitha. Formulation and evaluation of microspheres of an antihypertensive drug using natural polymers. *International Journal of Pharmacy and Pharmaceutical Sciences*, 2012; 2(4): 113-118
23. S. M. Sarode, M. Mittal, R. M. Magar; Formulation and evaluation of floating microspheres of glipizide. *Journal of chemical and pharmaceutical research*, 2011, 3(3):775-783
24. Awadhesh kumar maurya, vishalgupta, Development and evaluation of stable microsphere of Diltiazem hydrochloride an antihypertensive drug. *International journal of pharmacy & life sciences*, 2011; 2(2), 583-589
25. Navneet garud, Preparation and in-vitro evaluation of metformin microspheres using non-aqueous solvent evaporation technique. *Tropical journal of pharmaceutical research*, August 2012; 11(4): 577-583
26. R. Himabindu, N. Sriram Formulation and evaluation of glimepiride microspheres. *Journal of Global Trends in Pharmaceutical Sciences*, 3(4), 849-855
27. Rohit B Mane, Chandrakant L Bhingare, Mangesh R Bhalekar. Preparation and Evaluation of Carvedilol Microsphere by Spray Drying Technique Effect Of Process Parameters On Formulation. *International Journal of Pharmaceutical Quality Assurance*, 4 (1); 4-12
28. Solmaz and Ramin Khaksar. Formulation Optimization of Nifedipine Containing Microspheres Using Factorial Design. *African Journal Of Pharmacy and Pharmacology*, 2010; 4(6): 346-354
29. G Vradha, N. Formulation and evaluation of mucoadhesive microspheres of Nifedipine. *Journal of pharmaceutical and scientific innovation*, 2012; 1(5):39-43.
30. Faizi Muzaffar. Formulation and Evaluation of Mucoadhesive microspheres of Amoxicillin Trihydrate by using Eudragit RS 100. *International Journal of Chemtech Research*. Coden(usa) ijcrgg, 2010; 2(1): 466-470
31. M.S. Harsoliya, Formulation of Floating Microspheres of Ritonavir by Crosslinking-Technique Effect of NaHCO<sub>3</sub> as Gas Forming Agent. *International Journal of Pharmaceutical & Biological Archives*, 2012; 3(1):108-
32. Yüce, Kandemir Canefe. Indomethacin-Loaded Microspheres Preparation, Characterization and In-Vitro Evaluation Regarding Ethyl cellulose Matrix Material. *Turk J. Pharm. Sci.*, 2008; 5(3):129-142.
33. Ram Chand Dhakar, Girish Kumar, Vijay Kumar tilak. Design and Evaluation of Srm Microspheres of Metformin Hydrochloride. *Pharmacie Globale (IJCP)*, 2010; 1 (07):1-5.
34. Dr. Ar. Mullaicharam. Ascorbic Acid-Loaded Microspheres Preparation and Micromeritics Characterization. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2 (5):3984-3990.
35. Bipul Nath, Lila Kantanath. Design and development of Metformin HCl Floating Microspheres using two polymers of different permeability characteristics. *International Journal of Pharmaceutical Sciences and Nano Technology*, 2009; 2(2):627-637.

36. Nayak Bhabani Shankar and Nayak Udaya Kumar. Lamivudine Loaded Microspheres for Oral Use Design, Development and Establishment of In-vivo-In-vitro Correlation. *Asian Journal of Pharmaceutical and Clinical Research*, 2009; 2(1): 55-60.
37. Ahmed F, Abdel Wahab, Amal K. Hussein, Khaled A, Khaled, and Osama A. A. Ahmed. Meloxicam Preparation, Characterization and In-Vivo Evaluation, *International Journal of Pharmaceutical Sciences Review and Research*, 2013; 21(2): 38-45.
38. Mukul Sengupta. Formulation and Evaluation of Ethyl Cellulose Microsphere of Glipizide, *IJPRBS*, 2012; 1(3): 391-395.
39. S. Y. Lin, K. S. Chen, H. H. Teng, M. J. Li, In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. *J. Microencapsul*, 17(5): 577-586, (2000).
40. Jat RC1, Jain Suman, Dubey Subodh, Jain Vinay, Bhardwaj Sudhir, Jain Amit, Preparation and evaluation of colon targeting microspheres. *Journal of Pharmacy Research*, 3(3): 596-599, (2010).
41. S. K. Mehta, Gurpreet Kuar, Anil Verma, Fabrication of plant protein microsphere for encapsulation, stabilization and in vitro release of multiple anti-tuberculosis drugs. *Colloids and surfaces A: Physicochemical and Engineering Aspects*, 375: 219-230 (2011).
42. Hitendra S. Mahajan ?, Bhushankumar V. Tatiya, Pankaj P. Nerkar, Ondansetron loaded pectin based microspheres for nasal administration: In vitro and in vivo studies. *Powder Technology*, 221: 168-176, (2012).
43. Saravana Kumar A, NM Ramaswamy, Chitosan microsphere as potential vaccine delivery systems. *International Journal of drug delivery*, 3(1): 43-50, (2011).
44. A Saravanakumar, Sunita Minz, Madhulika Pradhan, Pavani Sure, Atul N Chandu, Umesh Mishra, Poly lactic Acid microsphere as a potential vaccine delivery system for the Tetanus toxoid: preparation and in vitro dissolution study. *Research j Pharm and tech*, 1(4): 453-459, (2008).
45. Libo yang, James S. Chu, Joseph A. Fix, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. *International journal of Pharmaceutics*, 235: 1-15, (2002).
46. Alf Lamprecht, Hiromitsu Yamamoto, Hirofumi Takeuchi, Yoshiaki Kawashima, Microsphere design for the colonic delivery of 5-fluorouracil. *Journal of Controlled Release*, 90: 313-322, (2003).
47. Illum L, Jones PD, Attachment of monoclonal antibodies to microspheres. *Methods Enzymol*, 112: 67-84, (1985).
48. Kirti Deshmukh, Solid porous microsphere: emerging trend in pharmaceutical technology, *International journal of pharma and biosciences*, 2(1): 364-377, (2011).
49. Wester RC, Patel R, Nacht S, Leyden J, Melendres J, Maibach H., Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. *J Am Acad Dermatol*, 1991, 24(5.1): 720-726, (1991).
50. Farah Jean-Jacques Toublan, Stephen Bopaart, Kenneth S. Suslick, tumor targeting by surface- modified protein microspheres. *J Am chem. Soc*, 128(11): 3472-3473, (2006).
51. Constantin M, Fundueanu G, Cortesi R, Esposito E, Nastruzzi C., Aminated polysaccharide microspheres as DNA delivery systems. *Drug Deliv*, 10(3): 139-149, (2003).
52. Keegan ME, Saltzman WM. Surface-modified biodegradable microspheres for DNA vaccine delivery. *Methods Mol Med*, 127: 107-113, (2006).
53. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR., A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. *Biomaterials*, 28(21): 3236-3244, (2007).
54. Andreas Zimmer, J&g Kreuter, Microspheres and nanoparticles used in ocular delivery systems. *Advanced Drug Delivery Reviews*, 16: 61-73, (1995).
55. Yun YH, Goetz DJ, Yellen P, Chen W., Hyaluronan microspheres for sustained gene delivery and site-specific targeting. *Biomaterials*, 25(1): 147-57, (2004).
56. Lamprecht, Hiromitsu Yamamoto, Hirofumi Takeuchi, Yoshiaki Kawashima, pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. *Journal of Controlled Release*, 98: 1-9, (2004).
57. Illum L, Farraj NF, Critchley H, Davis SS, Nasal administration of gentamicin using a Novel microsphere delivery system. *Int J Pharm*, 46: 261-265, (1998).
58. Ma N, Xu L, Wang Q, Zhang X, Zhang W, Li Y, Jin L, Li S. Development and evaluation of new sustained-release floating microspheres. *Int J Pharm*, 358(1-2): 82-90, (2008).